Use of Chloroquine and Hydroxychloroquine in COVID-19 and Cardiovascular Implications: Understanding Safety Discrepancies to Improve Interpretation and Design of Clinical Trials

Affiliations

¹ Division of Hematology and Oncology, Mayo Clinic, Rochester, MN (O.O.).
² Division of Cardiology, Department of Medicine, University of California at Los Angeles (E.H.Y.).
³ Center for Cardiovascular Analytics, Research and Data Science (CARDS), Providence Heart Institute, Providence St Joseph Health, Portland, OR (T.J.G.).
⁴ The Ciccarone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, Baltimore, MD (E.D.M., R.S.B.).
⁵ Department of Cardiovascular Medicine, Mayo Clinic & Mayo Clinic College of Medicine, Rochester, MN (B.J.G.).

Review

Ohad Oren et al. Circ Arrhythm Electrophysiol. 2020 Jun.

. 2020 Jun;13(6):e008688.

doi: 10.1161/CIRCEP.120.008688. Epub 2020 May 21.

¹ Division of Hematology and Oncology, Mayo Clinic, Rochester, MN (O.O.).
² Division of Cardiology, Department of Medicine, University of California at Los Angeles (E.H.Y.).
³ Center for Cardiovascular Analytics, Research and Data Science (CARDS), Providence Heart Institute, Providence St Joseph Health, Portland, OR (T.J.G.).
⁴ The Ciccarone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, Baltimore, MD (E.D.M., R.S.B.).
⁵ Department of Cardiovascular Medicine, Mayo Clinic & Mayo Clinic College of Medicine, Rochester, MN (B.J.G.).

No abstract available

Keywords: COVID-19; chloroquine; hydroxychloroquine; pandemic; trophozoites.

Figures

1. Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis. 2020;20:533–534. doi: 10.1016/S1473-3099(20)30120-1. - PMC - PubMed
1. Rolain JM, Colson P, Raoult D. Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century. Int J Antimicrob Agents. 2007;30:297–308. doi: 10.1016/j.ijantimicag.2007.05.015. - PMC - PubMed
1. Sullivan DJ, Jr, Gluzman IY, Russell DG, Goldberg DE. On the molecular mechanism of chloroquine’s antimalarial action. Proc Natl Acad Sci U S A. 1996;93:11865–11870. doi: 10.1073/pnas.93.21.11865. - PMC - PubMed
1. Vincent MJ, Bergeron E, Benjannet S, Erickson BR, Rollin PE, Ksiazek TG, Seidah NG, Nichol ST. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J. 2005;2:69. doi: 10.1186/1743-422X-2-69. - PMC - PubMed
1. Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, Liu X, Zhao L, Dong E, Song C, et al. In vitroantiviralactivity and projection of optimizeddosingdesign of hydroxychloroquine for the treatment of severeacuterespiratorysyndromecoronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020:ciaa237. doi: 10.1093/cid/ciaa237. - PMC - PubMed